Answers are grounded in this paper and cite their sources.
Background: Epigenetic targeting therapy, including histone deacetylase (HDAC) inhibitors and DNA-methyltransferase 1 (DNMT1) inhibitors, is a promising and attractive tool to treat advanced cancers, overcome drug resistance, and minimize adverse effects of traditional therapies. Objective: To investigate whether β-hydroxybutyrate enhanced the effectiveness of decitabine against colon cancer and enhanced the anti-cancer effect of decitabine against colon and prostate cancer cell lines. Methods: LS174T cells (colorectal cancer) and PC3 cells (prostate cancer) were seeded in a 96-well cell culture plate. Decitabine was used in six [100, 50, 25, 12.5, 6.25, & 3.125μg/ml] concentrations alone and combined with β-hydroxybutyrate, enhancing the effectiveness of decitabine against colon (2000μg/ml). After 48 hours of incubation, LS174T cells and PC3 cell viability were determined by MTT assay. DNMT1-enzyme level was measured using the DNMT1-ELISA kit. Results: For the LS174T cell line and PC3 cell line, the combination of decitabine plus β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and showed a significant (p<0.05) decrease in viability percent for all concentrations compared to the control group. Also, the comparison between decitabine monotherapy and decitabine plus β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and revealed a significant (p<0.05) difference in viability between the two groups. Finally, a significant (p<0.05) reduction in DNMT1 level was observed between monotherapy and combination therapy for all decitabine concentrations and for both cell lines. Conclusions: β-hydroxybutyrate enhanced the effectiveness of decitabine against colon and prostate cancers, suggesting that β-hydroxybutyrate may serve as a promising adjuvant to decrease decitabine therapeutic doses.
No takes yet. Share an insight, caveat, or question.
Obayes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: